Spravato Esketamine

SPRAVATO® (esketamine) CIII Nasal Spray is used in conjunction with an oral antidepressant, for the treatment of:
• Treatment-resistant depression (TRD) in adults.
• Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.

Together with an oral antidepressant, Spravato can provide relief from depressive symptoms much more quickly than traditional antidepressants, often within hours. It works differently than standard antidepressants, targeting the NMDA receptor, which may help patients who haven't responded to other treatments. Many patients experience significant improvement in mood and overall functioning, which can enhance quality of life. Spravato is administered as a nasal spray in a clinical setting, allowing for monitoring and immediate support.

FDA Approved: It has been approved specifically for TRD, highlighting its targeted efficacy for patients who have not found relief with other options.

These benefits make Spravato a valuable option for individuals struggling with severe depression that has not responded to conventional therapies.